Search

Your search keyword '"HARALD DARIUS"' showing total 267 results

Search Constraints

Start Over You searched for: Author "HARALD DARIUS" Remove constraint Author: "HARALD DARIUS"
267 results on '"HARALD DARIUS"'

Search Results

1. Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance

2. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

3. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

4. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

5. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study

6. Is it Time to Transform Our Treatment Of Type 2 Diabetes

7. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

9. 36-month clinical outcomes of patients with venous thromboembolism

10. Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance

11. Diabetes und kardiovaskuläre Ereignisse

12. Empagliflozin in Patients with Chronic Kidney Disease

13. Duale Thrombozytenhemmung nach akutem Koronarsyndrom oder perkutaner Koronarintervention – womit und wie lange?

14. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

15. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.

16. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

17. Empfehlungen zur prähospitalen Behandlung des akuten Koronarsyndroms bei Patienten unter Dauertherapie mit neuen oralen Antikoagulanzien (NOAKs)

18. Vorhofflimmern und Antikoagulation im Alter

19. Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern

20. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin

21. The total amount of CRP within the first 72 h after STEMI is crucial for the outcome

22. [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?]

23. [Prevention of venous thromboembolism in COVID-19 outpatients]

24. Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern

25. Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs

26. Improving care coordination for patients with cardiac disease: Study protocol of the randomised controlled new healthcare programme (Cardiolotse)

27. C-reactive protein increases myocardial damage after STEMI

28. Medikamentöse Thrombose-Prophylaxe bei ambulanten COVID-19-Patienten

29. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study

30. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation]

31. 2230Results from the CAMI1 Study: selective CRP apheresis as a new treatment option in acute myocardial infarction

32. Blutungen unter direkten oralen Antikoagulanzien

33. Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

34. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

35. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

36. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

37. THE TOTAL AMOUNT OF CRP WITHIN THE FIRST 72 H AFTER STEMI IS CRUCIAL FOR THE OUTCOME

38. The Changing Landscape for Stroke Prevention in AF

39. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

40. Vorhofohrverschluss für Patienten mit Vorhofflimmern

42. Procedural Success Rates and Mortality in Elderly Patients With Percutaneous Coronary Intervention for Cardiogenic Shock

43. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

44. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

45. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

46. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

47. Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern

48. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. für 'Brustschmerz-Ambulanzen'

49. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy

50. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Catalog

Books, media, physical & digital resources